Supplementary Online Content

Yu S, Fan Z, Ma L, et al. Association between measurable residual disease in patients with intermediate-risk acute myeloid leukemia and first remission, treatment, and outcomes. *JAMA Netw Open.* 2021;4(7):e2115991. doi:10.1001/jamanetworkopen.2021.15991

eTable. Causes of Death Posttransplantation **eFigure.** Forest Plots for Survival of MSD-SCT and AD-SCT

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable. Causes of Death Posttransplantation

Cause of death	CMT group	auto-SCT	allo-SCT group
		group	
	no. (%)	no. (%)	no. (%)
Relapse	58(89.2)	24(82.8)	28 (45.9)
GVHD-related			
aGVHD	1(1.5)*	0(0)	8(13.1)
cGVHD	0(0)	0(0)	5(8.2)
Treatment-related			
Infections	5 (7.7)	5 (17.2)	13 (21.3)
others	1(1.5)	0(0)	7(11.5)

Abbreviations: CMT, chemotherapy; auto-SCT, autologous stem cell transplantation; allo-SCT, allogeneic stem cell transplantation.

^{*}Some patients received allo-SCT as salvage treatment in CMT group and one died of aGVHD

a Subgroup	MSD-SCT(n)	AD-SCT(n)		Hazard ratio(95%CI)	p-value
	Events(n)/patients(N)	Events(n)/patients((N)		
All patients	32/133	35/146	H	1.035(0.641-1.671)	0.889
Subgroup A	1/20	3/21	-	3.177(0.330-30.542)	0.317
Subgroup B	16/36	14/41	H-1	0.799(0.390-1.639)	0.541
Subgroup C	5/16	5/15		1.139(0.330-3.935)	0.837
Subgroup D	6/40	7/45		0.988(0.332-2.940)	0.983
Subgroup E	4/21	6/24		1.404(0.396-4.976)	0.599
			Favour AD-SCT Favour MSD-SCT		
b					
Subgroup	MSD-SCT	AD-SCT		Hazard ratio(95%CI)	p-value
	Deaths(n)/patients(N)	Deaths(n)/patients((N)		
All patients	29/133	32/146	H=-1	1.060(0.640-1.749)	0.826
Subgroup A	1/20	3/21	-	3.184(0.331-30.621)	0.316
Subgroup B	15/36	12/41		0.729(0.341-1.557)	0.414
Subgroup C	5/16	4/15		0.857(0.230-3.194)	0.818
Subgroup D	4/40	7/45		1.599(0.468-5.463)	0.888
Subgroup E	4/21	6/24		1.446(0.408-5.126)	0.568
		F	Favour AD-SCT Favour MSD-SCT		
C Subgroup	MSD-SCT(n)	AD-SCT(n)		Hazard ratio(95%CI)	p-value
	Events(n)/patients(N)	Events(n)/patients((N)		
All patients	52/133	69/146	 - 	1.354(0.944-1.940)	0.099
Subgroup A	5/20	7/21	⊢	1.485(0.471-4.683)	0.499
Subgroup B	21/36	22/41		1.003(0.551-1.825)	0.993
Subgroup C	7/16	9/15	H	1.885(0.701-5.069)	0.209
Subgroup D	11/40	19/45	1	1.581(0.753-3.324)	0.226
Subgroup E	8/21	12/24	—	1.504(0.614-3.680)	0.372
		F	Favour AD-SCT Favour MSD-SCT		

Abbreviations: MSD-SCT, matched sibling donor stem cell transplant; AD-SCT, alternative donor stem cell transplant.

Subgroup A, patients who become MRD negative after one course of chemotherapy and had persistently negative MRD; subgroup B, persistently positive MRD; subgroup C, recurrent MRD+ patients after being MRD-; subgroup D, patients who become MRD negative after two courses of chemotherapy; subgroup E, patients who become MRD negative after three courses of chemotherapy.